RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
In Vitro Activity
RSL3 (0-8 μM, 72 hours) potently reduces the viability of HN3 cells, with IC50s of 0.48 µM in HN3 and 5.8 µM in HN3-rslR cells, respectively.
RSL3 (0-8 μM, 24 hours) reduces the expression of GPX4 protein, increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
In Vivo Activity
RSL3 (100 mg/kg, Intratumorally twice per week for 20 days) significantly inhibits the growth of tumor in combination with trigonelline in mice bearing HN3R cells.
Storage & Handling
Storage
4 °C, sealed storage, away from moisture
In solvent : -80 °C, 6 months; -20 °C, 1 month (sealed storage, away from moisture)
Shipping
Room temperature in continental US; may vary elsewhere.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.